Clinical Trial Update: A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

A first-in-human Phase 1 study of KK2223 in relapsed or refractory T-cell non-Hodgkin lymphoma (PTCL or CTCL) is planned, with the trial currently not yet recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• KK2223

Snippet

Sponsor: Kyowa Kirin, Inc. | Conditions: T-cell NHL (PTCL or CTCL) | Phase 1 | Status: NOT_YET_RECRUITING